SWOG clinical trial number
S0601
A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma
100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Published
Abbreviated Title
NON-HODGKINS: R-CHOP-V followed by VM maintenance therapy for MCL
Activated
08/15/2006
Closed
06/01/2008
Participants
Research committees
Lymphoma
Treatment
Rituximab
Bortezomib
CHOP
Eligibility Criteria Expand/Collapse
Publication Information Expand/Collapse
Other Clinical Trials
S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
21% Accrual
Accrual
21%
Open
Phase
S2207
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
06/30/2023
12% Accrual
Accrual
12%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase